JP7379390B2 - 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ - Google Patents

癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ Download PDF

Info

Publication number
JP7379390B2
JP7379390B2 JP2020570163A JP2020570163A JP7379390B2 JP 7379390 B2 JP7379390 B2 JP 7379390B2 JP 2020570163 A JP2020570163 A JP 2020570163A JP 2020570163 A JP2020570163 A JP 2020570163A JP 7379390 B2 JP7379390 B2 JP 7379390B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
lif
seq
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533084A5 (enExample
JP2021533084A (ja
Inventor
ジョアン・セオアネ・スアレス
ジュディット・アニド・フォルゲイラ
ロビン・マシュー・ハレット
パトリシア・アン・ギブリン
ジェンヌ・マグラム
ナイミシュ・パーンディヤ
ロバート・ワッサーマン
アンガス・シンクレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Original Assignee
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institut d'Investigació Oncològica Vall-Hebron, MedImmune Ltd filed Critical Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
Publication of JP2021533084A publication Critical patent/JP2021533084A/ja
Publication of JP2021533084A5 publication Critical patent/JP2021533084A5/ja
Priority to JP2023187689A priority Critical patent/JP7603772B2/ja
Application granted granted Critical
Publication of JP7379390B2 publication Critical patent/JP7379390B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020570163A 2018-06-18 2019-06-17 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ Active JP7379390B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023187689A JP7603772B2 (ja) 2018-06-18 2023-11-01 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18
EP18382432.5 2018-06-18
PCT/IB2019/000812 WO2019243900A2 (en) 2018-06-18 2019-06-17 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023187689A Division JP7603772B2 (ja) 2018-06-18 2023-11-01 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ

Publications (3)

Publication Number Publication Date
JP2021533084A JP2021533084A (ja) 2021-12-02
JP2021533084A5 JP2021533084A5 (enExample) 2022-06-24
JP7379390B2 true JP7379390B2 (ja) 2023-11-14

Family

ID=62837845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570163A Active JP7379390B2 (ja) 2018-06-18 2019-06-17 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
JP2023187689A Active JP7603772B2 (ja) 2018-06-18 2023-11-01 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023187689A Active JP7603772B2 (ja) 2018-06-18 2023-11-01 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ

Country Status (12)

Country Link
US (1) US20210187106A1 (enExample)
EP (1) EP3806899A2 (enExample)
JP (2) JP7379390B2 (enExample)
KR (1) KR20210022065A (enExample)
CN (1) CN112955178B (enExample)
AU (2) AU2019291307B2 (enExample)
CA (1) CA3103369A1 (enExample)
EA (1) EA202092964A1 (enExample)
IL (1) IL279444A (enExample)
MA (1) MA52300A (enExample)
SG (1) SG11202012576QA (enExample)
WO (1) WO2019243900A2 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
WO2016168440A1 (en) 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3794031A2 (en) * 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523796A (ja) 2010-04-05 2013-06-17 フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ バル デブロン（ウベアチェイーオー） ヒト白血病阻害因子（ｌｉｆ）を認識する抗体および望ましくない細胞増殖に関連する疾患の治療における抗ｌｉｆ抗体の使用
JP2017527582A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
WO2016168440A1 (en) 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer

Also Published As

Publication number Publication date
CN112955178A (zh) 2021-06-11
JP7603772B2 (ja) 2024-12-20
JP2024023212A (ja) 2024-02-21
MA52300A (fr) 2021-04-21
EP3806899A2 (en) 2021-04-21
WO2019243900A3 (en) 2020-03-05
AU2019291307B2 (en) 2024-04-04
JP2021533084A (ja) 2021-12-02
AU2024204564A1 (en) 2024-07-18
CN112955178B (zh) 2025-03-11
WO2019243900A2 (en) 2019-12-26
US20210187106A1 (en) 2021-06-24
KR20210022065A (ko) 2021-03-02
EA202092964A1 (ru) 2021-03-30
CA3103369A1 (en) 2019-12-26
AU2019291307A1 (en) 2021-02-04
IL279444A (en) 2021-01-31
SG11202012576QA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US10583191B2 (en) Antibodies against LIF and uses thereof
JP7459173B2 (ja) Ｌｉｆに対する抗体及びその使用
JP2024160301A (ja) Ｌｉｆに対する抗体及びそれらの投与形態
JP7603772B2 (ja) 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
HK40056275A (en) Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
HK40042216A (en) Antibodies against lif and dosage forms thereof
HK40040276B (en) Antibodies against lif and uses thereof
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo
EA051297B1 (ru) Антитела к lif и их применения
EA045781B1 (ru) Антитела к lif и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231101

R150 Certificate of patent or registration of utility model

Ref document number: 7379390

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150